Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nulixir Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners but 3 distinct art units, showing broad examiner distribution within a more limited set of technical examination groups.
WORSHAM, JESSICA N is the busiest examiner, with 1 pending matter. No examiner has a larger identified workload, so counsel should coordinate consistent portfolio positions while preserving matter-specific responses.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | — |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17945036 | STABLE NON-AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | STEVENS, MARK V | 23d overdue |
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | — |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | — |
| 17945037 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | KIM, DANIELLE A | — |
| 17470994 | METHODS AND SYSTEMS FOR FORMING MULTI-LAYERED PARTICLES | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1613 | 2 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | 1615 | §102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 17945036 | STABLE NON-AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | STEVENS, MARK V | 1613 | §103 | Final Rejection | 23d overdue | Pending | Sep 14, 2022 |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Non-Final OA | — | Pending | Sep 14, 2022 |
| 17945037 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | KIM, DANIELLE A | 1613 | §103 | Final Rejection | — | Pending | Sep 14, 2022 |
| 17470994 | METHODS AND SYSTEMS FOR FORMING MULTI-LAYERED PARTICLES | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | — | Pending | Sep 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNulixir Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Jessica N Worsham has the most, with 1 of Nulixir Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
